Montelukast Mylan Generics (Montelukast)

Montelukast acts on the leukotriene pathway to manage chronic respiratory conditions.

• Asthma: reduces the frequency of asthma attacks and improves overall lung function.
• Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergens.
• Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity, allowing better exercise tolerance.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, C4 and E4 from binding. This inhibition reduces bronchoconstriction, mucus secretion, vascular permeability, and inflammatory cell recruitment in the airways, thereby improving respiratory function and decreasing allergic inflammation.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate pain often reported during early treatment.
• Abdominal pain: discomfort or cramps in the stomach area.
• Cough: occasional irritation of the throat.
• Dizziness: transient sensation of light‑headedness.
• Fatigue: feeling unusually tired.
• Nausea: mild upset stomach.

Serious or Rare Side Effects

• Allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention.
• Neuropsychiatric events: mood changes, depression, or suicidal thoughts.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
• Bronchospasm: paradoxical worsening of breathing.
• Blood dyscrasias: rare cases of eosinophilia or neutropenia.

Before initiating therapy, consider the following safety measures.

• Liver function assessment: evaluate hepatic status, especially in patients with known liver disease.
• Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation.
• Acute asthma attacks: do not use as rescue medication; provide a fast‑acting bronchodilator instead.
• Hypersensitivity: avoid if the patient has known allergy to montelukast or any tablet excipients.
• Drug interactions: review concomitant medications that may alter montelukast levels.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma concentrations.
• Phenobarbital or rifampicin: potent inducers that can reduce therapeutic levels.
• Antidepressants (e.g., fluoxetine) combined with other leukotriene antagonists: heightened risk of neuropsychiatric effects.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR; monitor coagulation parameters.
• Other leukotriene modifiers (zafirlukast, zileuton): additive effects on leukotriene pathways.
• Oral contraceptives: minor impact on hormone levels; observe for menstrual changes.
• Theophylline: monitor for increased side‑effects, though interaction is limited.
• Antifungal agents (e.g., fluconazole): may modestly raise montelukast levels.